← Back to patent-cliff list
异麦芽糖酐铁
Tier C — Watch / tradeIron Isomaltoside
Pharmacosmos A/S
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Not applicable
Brand：Isofer、Monoferric、Diafer、Jilazo、Mono ver、Monofer、Monover
Indications (approved)：缺铁性贫血
Regional status
US
批准上市
2020-01-16
EU
无进展
2007-05-01
China
批准上市
2021-01-30
Japan
批准上市
2022-03-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Iron Isomaltoside?
Approved indications include: 缺铁性贫血.
When does the Iron Isomaltoside patent expire?
No public expiry year is available for Iron Isomaltoside yet; this page updates once verified.
How do I get a quote for Iron Isomaltoside intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24